Recombinant Human Myc proto-oncogene protein (MYC), partial

1. the findings of this study demonstrate that hsamiR24 suppresses metastasis in nasopharyngeal carcinoma by regulating the cMyc/EMT axis, suggesting that hsamiR24 may be used as a prognostic factor and as a novel target for the prevention of nasopharyngeal carcinoma metastasis. PMID: 30226609
2. lncRNA THOR is up-regulated in retinoblastoma, and its over-expression significantly enhances the malignant phenotype transformation of retinoblastoma cells by up-regulating c-myc and TGF2BP1 expression. PMID: 30119193
3. we demonstrate that neither MYC IHC nor MYC FISH alone is a sufficient screening mechanism for identification of the clinically relevant entities of HGBLwR or DEL PMID: 28868942
4. Because RPL23 is encoded by a target gene of c-Myc, the RPL23/Miz-1/c-Myc regulatory circuit provides a feedback loop that links efficient RPL23 expression with c-Myc's function to suppress Miz-1-induced Cdk inhibitors and thereby leads to apoptotic resistance in higher-risk myelodysplastic syndrome patients. PMID: 28539603
5. GATAD2B interacts with C-MYC to enhance KRAS driven tumor growth. PMID: 30013058
6. low expression of c-Myc protein predicts poor outcomes in patients with HCC with hepatectomy. PMID: 29690860
7. Combined, these findings suggest that c-Myc could transcriptionally regulate TCRP1 in cell lines and clinical samples and identified the c-Myc-TCRP1 axis as a negative biomarker of prognosis in tongue and lung cancers. PMID: 28623290
8. Kazakh and Han patients with esophageal squamous cell carcinoma with Glut1 c-myc co-expression had poorer prognosis. PMID: 29629851
9. MYC activation in papillary clear cell renal cell carcinoma leads to a worse prognosis. PMID: 28593993
10. could not find any relationship between Bcl-2, c-Myc and EBER-ISH positivity and the low/high IPS groups in classical Hodgkin lymphoma PMID: 29708579
11. Fluorescence in situ hybridization studies (histologic sections) confirmed translocations of MYC (8q24), BCL2 (18q21) and BCL6 (3q27) in all patients. PMID: 30043475
12. topical mevastatin accelerates wound closure by promoting epithelialization via multiple mechanisms: modulation of GR ligands and induction of the long noncoding RNA Gas5, leading to c-Myc inhibition. PMID: 29158265
13. CCND1 , C-MYC , and FGFR1 amplifications were observed in 34.28%, 28.57%, and 17.14% of the 35 samples (invasive ductal breast carcinoma). PMID: 30119151
14. Data suggest that MYC induction of REV-ERBalpha is both persistent and recurrent across many inducible MYC model systems. PMID: 28332504
15. HUWE1 overexpression could functionally suppress prostate carcinoma development both in vitro and in vivo, possibly by inverse regulation of c-Myc. PMID: 29966975
16. Menin functions as an oncogenic regulatory factor that is critical for MYC-mediated gene transcription. PMID: 28474697
17. High c-myc expression is associated with colorectal cancer. PMID: 30015962
18. Melatonin disturbs SUMOylation-mediated crosstalk between c-Myc and nestin via MT1 activation and promotes the sensitivity of paclitaxel in brain cancer stem cells. PMID: 29654697
19. FBP1 modulates the sensitivity of pancreatic cancer cells to BET inhibitors by decreasing the expression of c-Myc. These findings highlight FBP1 could be used as a therapeutic niche for patient-tailored therapies PMID: 30201002
20. miR135a directly bound to UCA1 and the 3' untranslated region of cmyc, and UCA1 competed with cmyc for miR135a binding. PMID: 30015867
21. MYC directly regulates DANCR and plays important role in cancer cell proliferation. PMID: 29180471
22. In this review, we provide support to the hypothesis that the cooperation of c-Myc with transcriptional cofactors mediates c-Myc-induced cellular functions. We produce evidence that recently identified cofactors are involved in c-Myc control of survival mechanisms of cancer cells PMID: 30261904
23. 4-chlorobenzoyl berbamine (CBBM) inhibits the JAK2/STAT3 pathway, leading to reduced c-Myc transcription. Collectively, these findings suggest that CBBM could be a promising lead compound for treatment of c-Myc-driven diffuse large B cell lymphoma. PMID: 30099568
24. Results revealed that C-MYC protein is highly expressed in colon cancer tissues, mainly in the cell nucleus and was identified as a direct target for mir-184. C-MYC appeared to participate in cell cycle regulation and malignant transformation to colon cancer. PMID: 28782841
25. MACC1 and c-Myc are highly expressed in serum and tumor tissues of EC patients. Both are correlated with TNM stage, primary infiltration, and lymph node or distal metastasis. PMID: 29984790
26. study provides an interesting example using chemical biological approaches for determining distinct biological consequences from inhibiting vs. activating an E3 ubiquitin ligase and suggests a potential broad therapeutic strategy for targeting c-MYC in cancer treatment by pharmacologically modulating cIAP1 E3 ligase activity. PMID: 30181285
27. The data demonstrated that 10058F4, a cMyc inhibitor, increased the growth inhibition, G0/G1 phase arrest and apoptosis of the NALM6 and CEM cells as induced by dexamethasone (DXM), a type of GC. PMID: 29749488
28. c-MYC/BCL2 protein co-expression is associated with non-germinal center B-cell in Diffuse Large B-Cell Lymphoma PMID: 29801406
29. c-Myc was capable of upregulating HP1gamma by directly binding to the E-box element in the first intron of HP1gamma gene, and the upregulated HP1gamma, in turn, repressed the expression of miR-451a by enhancing H3K9 methylation at the promoter region of miR-451a. PMID: 28967902
30. A subset of pancreatic acinar cell carcinomas shows c-MYC alterations including gene amplification and chromosome 8 polysomy. PMID: 29721608
31. Expression and Clinical Significance of LC-3 and P62 in Non-small Cell Lung Cancer PMID: 29945702
32. The findings of the current study demonstrate presence of the IDH1 R132H mutation in primary human glioblastoma cell lines with upregulated HIF-1alpha expression, downregulating c-MYC activity and resulting in a consequential decrease in miR-20a, which is responsible for cell proliferation and resistance to standard temozolomide treatment. PMID: 29625108
33. a novel signal circuit of Stat3/Oct-4/c-Myc was identified for regulating stemness-mediated Doxorubicin resistance in triple-negative breast cancer PMID: 29750424
34. MYC amplification and MYC overexpression occurred almost exclusively in secondary cutaneous angiosarcoma in our series. PMID: 29135507
35. High c-myc expression is associated with the development of prostate cancer. PMID: 29554906
36. Circular RNA hsa_circRNA_103809 promotes lung cancer progression via facilitating ZNF121-dependent MYC expression by sequestering miR-4302. PMID: 29698681
37. s conclude that quantitative measurements of intratumor heterogeneity by multiplex FISH, detection of MYC amplification and TP53 mutation could augment prognostication in breast cancer patients. PMID: 29181861
38. PCYT1A was upregulated by MYC, which resulted in the induction of aberrant choline metabolism and the inhibition of B-lymphoma cell necroptosis. PMID: 28686226
39. Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas. PMID: 28665415
40. CD30+ diffuse large B-cell lymphoma has characteristic clinicopathological features mutually exclusive with MYC gene rearrangement and negatively associated with BCL2 protein expression. PMID: 29666157
41. High MYC amplification is associated with HER2 positive breast cancers in African American women. PMID: 29523126
42. These data suggest that MYC acts as a master coordinator that inversely modulates the impact of cell cycle and circadian clock on gene expression via its interaction with MIZ1. PMID: 27339797
43. In our study, the c-myc oncogene was amplified in 11.1% of BPH samples. Bivariate analysis failed to reveal any significant association between oncogene amplification and the clinicopathologic variables examined. PMID: 29234244
44. Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF1A and HIF1B binding to a MYC enhancer. PMID: 27774982
45. Data indicate that miR-34a enhanced the sensitivity to cisplatin by upregulation of c-Myc and Bim pathway. PMID: 29060932
46. Luciferase reporter assay showed that c-Myc, an oncogene that regulating cell survival, angiogenesis and metastasis, was a direct target of miR-376a. Over-expression of miR-376a decreased the mRNA and protein levels of c-Myc in A549 cells. PMID: 28741879
47. The present findings show that expression of c-MYC has prognostic value in squamous cell carcinoma of the tongue, and could be useful in choice of therapy. PMID: 28393404
48. Multivariable analysis indicated that IPI (P = 0.002), chemotherapy regimens (P = 0.017), and MYC gene rearrangements (P = 0.004) were independent adverse prognostic factors for all diffuse large B cell Lymphoma(DLBCL) patients in this study. Results demonstrated that the poor survival of DLBCL patients with HBV infection was closely involved in chemotherapy regimens, IPI, and MYC gene rearrangements PMID: 29209623
49. MYC extra copy in diffuse large B-cell lymphoma is an independent poor prognostic factor PMID: 28776574
50. The c-Myc/miR-200b/PRDX2 loop regulates colorectal cancer (CRC) progression and its disruption enhances tumor metastasis and chemotherapeutic resistance in CRC. PMID: 29258530

显示更多

收起更多

HGNC: 7553

OMIM: 113970

KEGG: hsa:4609

STRING: 9606.ENSP00000367207

UniGene: Hs.202453